- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02027753
Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy (TED)
August 26, 2015 updated by: Sanofi
Efficacy and Safety of TrEating Type 2 Diabetic Patients With Inadequate Response to Metformin and DPP-4 Inhibitors by Adding Basal Insulin Therapy (Insulin Glargine)
Primary Objective:
To investigate the efficacy(HbA1c) at 6 months after adding basal insulin therapy (insulin glargine) to dipeptidyl peptidase-IV (DPP-IV) and metformin plus or minus sulphonylurea
Secondary Objectives:
- To assess the efficacy by adding insulin glargine
- To assess insulin dose
- Safety
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
28 weeks (Screening: About 2 weeks/Treatment: 24 weeks (6 months)/Follow-up: 2 weeks)
Study Type
Interventional
Enrollment (Actual)
109
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Sanofi-Aventis Administrative Office
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria :
- Patients with type 2 Diabetes mellitus ≥ 20 aged
- Patients who are treated with DPP- 4 for at least 3 months before informed consent with metformin plus or minus sulphonylurea inadequately controlled with HbA1c ≥ 7.5%
- Be able and voluntarily agree to participate in this study by signing a written informed consent
Exclusion criteria:
- Diabetes patients other than Type 2 (eg. Type 1 Diabetes mellitus, pancreatic disease, secondary diabetes)
- HbA1c > 11% at screening
- History of continuous basal insulin treatment within 1 year before screening
- History of diabetic acidosis (including keto-acidosis) within 1 year before screening
- History of myocardial infarct, stroke or heart failure related admission within 3 months before screening
- History of drug or alcoholic abuse within 6 months before screening
- Weight change ≥ 5 kg within 3 months before screening
- History of hypoglycemic unawareness
- Systolic blood pressure >180 mmHg or diastolic blood pressure > 110 mmHg regardless of taking anti-hypertensive, or uncontrolled hypertension
- Active malignant cancer, major systemic disease, clinically significant diabetic retinopathy, macular edema necessitating laser treatment, abnormal clinical finding from physical examination, lab analysis, electrocardiogram or vital sign, which can be regarded as to prevent safe completion of clinical study or to make efficacy assessment difficult by investigator or co-investigator at screening
- Pregnant or lactating women
- Women of child bearing potential (Pre-menopause or not surgically infertile within 3 months before screening) who match two conditions below:
- Negative serum pregnancy test at screening
- Using medically proven effective contraceptive method
- Hypersensitivity to investigational drugs
- Lab finding at screening:
- Abnormal liver function: Alanine transaminase or Alkaline phosphatase > 3 times of upper limit of normal range
- Renal insufficiency: Men with serum Cr ≥ 1.5 mg/dL (≥ 133µmol/L), women with serum Cr ≥ 1.4 mg/dL (≥ 124 µmol/L)
- Use of anti-obese drug within 3 months before screening
- Has been using drugs that can influence glucose metabolism (systemic corticosteroid, thyroid hormone) within 3 months before screening or has possibility of using these drug during the investigational period
- Has participated in clinical studies of any investigational drugs within 3 months before screening
- Considered not physically or psychologically appropriate to participate in clinical study by investigator
- Not willing to comply with scheduled visit, self-inject insulin, or self-monitor blood glucose level
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Insulin glargine and Oral anti diabetic treatment(s)
|
Pharmaceutical form: solution Route of administration: subcutaneous
Pharmaceutical form: tablet Route of administration: oral
Pharmaceutical form: tablet Route of administration: oral
Pharmaceutical form: tablet Route of administration: oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Response rate (percentage of patients who meet the target HbA1c ≤7%) at week 24 (6 months) after adding insulin therapy
Time Frame: week 24 (6 months)
|
week 24 (6 months)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of patients with HbA1c ≤7%
Time Frame: week 12 (3 months)
|
week 12 (3 months)
|
Change from baseline in HbA1c
Time Frame: week 12 (3 months), week 24 (6 months)
|
week 12 (3 months), week 24 (6 months)
|
Percentage of patients with HbA1c ≤6.5%
Time Frame: week 12 (3 months), week 24 (6 months)
|
week 12 (3 months), week 24 (6 months)
|
Change from baseline in Fasting Plasma glucose (FPG), 2hr-Postprandial Plasma Glucose
Time Frame: week 12 (3 months), week 24 (6 months)
|
week 12 (3 months), week 24 (6 months)
|
Total daily insulin dose
Time Frame: week 24 (6 months)
|
week 24 (6 months)
|
Fasting blood glucose (FBG) values
Time Frame: During 3 consecutive days before baseline, week 12, Week 24
|
During 3 consecutive days before baseline, week 12, Week 24
|
7-point Self Monitoring of Blood Glucose
Time Frame: During 2 days within 7 days before baseline, week 12, week 24
|
During 2 days within 7 days before baseline, week 12, week 24
|
Weight change from baseline
Time Frame: week 24 (6 months)
|
week 24 (6 months)
|
Number of Patients with Hypoglycemic Events
Time Frame: up to 6 months
|
up to 6 months
|
Number of Patients with Adverse Events
Time Frame: up to 6 months
|
up to 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2013
Primary Completion (Actual)
April 1, 2015
Study Completion (Actual)
April 1, 2015
Study Registration Dates
First Submitted
January 3, 2014
First Submitted That Met QC Criteria
January 3, 2014
First Posted (Estimate)
January 6, 2014
Study Record Updates
Last Update Posted (Estimate)
August 27, 2015
Last Update Submitted That Met QC Criteria
August 26, 2015
Last Verified
August 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Metformin
- Insulin Glargine
- Dipeptidyl-Peptidase IV Inhibitors
Other Study ID Numbers
- LANTUL06638
- U1111-1149-1632 (Other Identifier: UTN)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on INSULIN GLARGINE
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2United States, Poland, Puerto Rico, Canada, Hungary, Germany, Turkey, Greece
-
SanofiCompleted
-
IRCCS San RaffaeleTerminatedType 2 Diabetes Mellitus | Peripheral Vascular DiseaseItaly
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany
-
SanofiCompletedDiabetes Mellitus Type 2Germany
-
Johns Hopkins UniversityTerminatedHypoglycemia | Type 1 DiabetesUnited States
-
University of AarhusCompletedDiabetes Mellitus, Type 1Denmark
-
SanofiCompleted
-
Medical University of GrazCompletedDiabetes Mellitus, Type 2Austria
-
SanofiCompletedType 1 Diabetes MellitusUnited States, Canada, Czech Republic, Denmark, Estonia, Finland, Hungary, Japan, Latvia, Netherlands, Puerto Rico, Romania, Sweden